Surrozen, Inc. $SRZN Stock Position Lowered by Eversept Partners LP

Eversept Partners LP decreased its position in Surrozen, Inc. (NASDAQ:SRZN) by 38.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,624 shares of the company’s stock after selling 36,662 shares during the quarter. Eversept Partners LP owned about 0.50% of Surrozen worth $1,708,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of SRZN. China Universal Asset Management Co. Ltd. raised its position in Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares in the last quarter. Citadel Advisors LLC grew its stake in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Surrozen in the 4th quarter worth approximately $99,000. Schonfeld Strategic Advisors LLC raised its holdings in shares of Surrozen by 8.1% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 74,645 shares of the company’s stock worth $1,687,000 after purchasing an additional 5,621 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

Surrozen Stock Up 0.4%

SRZN stock opened at $19.81 on Tuesday. Surrozen, Inc. has a 12-month low of $8.70 and a 12-month high of $35.00. The company has a 50 day moving average of $23.72 and a two-hundred day moving average of $25.28. The company has a market cap of $229.99 million, a price-to-earnings ratio of -0.53 and a beta of 0.51.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Wednesday, May 6th. The company reported ($11.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The business had revenue of $5.00 million during the quarter, compared to analysts’ expectations of $4.00 million. On average, research analysts anticipate that Surrozen, Inc. will post -7.2 EPS for the current year.

Insider Activity at Surrozen

In other Surrozen news, COO Charles O. Williams sold 2,036 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $67,859.88. Following the completion of the sale, the chief operating officer owned 16,571 shares of the company’s stock, valued at $552,311.43. The trade was a 10.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Yang Li sold 1,584 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $52,794.72. Following the completion of the sale, the vice president owned 17,216 shares of the company’s stock, valued at approximately $573,809.28. This trade represents a 8.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 8,144 shares of company stock valued at $271,440. 31.74% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

SRZN has been the subject of a number of research reports. Zacks Research cut shares of Surrozen from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. HC Wainwright reaffirmed a “buy” rating and issued a $44.00 price target (up from $36.00) on shares of Surrozen in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Friday, July 17th. Finally, TD Cowen assumed coverage on Surrozen in a report on Tuesday, April 21st. They set a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Surrozen has an average rating of “Moderate Buy” and an average price target of $42.00.

Surrozen Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.